Cosentyx (secukinumab) is a medication used to treat various autoimmune conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. The drug works by targeting and blocking a specific protein that causes inflammation in the body.

Regarding the use of Cosentyx in elderly patients, there is limited information available in the provided sources. The drug patent information [1] does not mention any age restrictions or precautions related to the use of Cosentyx in elderly patients. However, it is important to note that the safety and efficacy of Cosentyx in elderly patients have not been specifically studied.

A study published in the Journal of the American Academy of Dermatology [2] evaluated the safety and efficacy of Cosentyx in elderly patients with moderate to severe psoriasis. The study included patients aged 65 years and older and found that Cosentyx was generally well-tolerated and effective in this population. However, the study was limited by its small sample size and short duration.

Another study published in the Journal of Clinical and Aesthetic Dermatology [3] evaluated the safety and efficacy of Cosentyx in patients with psoriasis aged 65 years and older compared to younger patients. The study found that the safety and efficacy of Cosentyx were similar between the two age groups.

In conclusion, while there is limited information available on the use of Cosentyx in elderly patients, the available studies suggest that the drug is generally well-tolerated and effective in this population. However, further studies are needed to confirm these findings and to determine any specific age-related precautions or dosage adjustments. As with any medication, it is important for elderly patients to discuss the risks and benefits of Cosentyx with their healthcare provider before starting treatment.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://pubmed.ncbi.nlm.nih.gov/29404966/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847154/